Driehaus Capital Management LLC Has $30.88 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Driehaus Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 2.8% in Q1, holding 852,657 shares valued at approximately $30.9 million.
• Several institutional investors, including GAMMA Investing LLC and Covestor Ltd, also increased their positions, signaling strong institutional interest in the company.
• Analyst ratings for Ultragenyx Pharmaceutical reflect a consensus rating of "Moderate Buy" with an average price target of $81.50, despite some recent target price reductions from various brokerages.

Driehaus Capital Management LLC increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 2.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 852,657 shares of the biopharmaceutical company's stock after buying an additional 23,192 shares during the quarter. Driehaus Capital Management LLC owned approximately 0.90% of Ultragenyx Pharmaceutical worth $30,875,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in RARE. Vestal Point Capital LP boosted its holdings in shares of Ultragenyx Pharmaceutical by 100.0% in the 4th quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company's stock valued at $63,105,000 after buying an additional 750,000 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Ultragenyx Pharmaceutical by 28.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock worth $116,559,000 after purchasing an additional 706,519 shares during the period. Deep Track Capital LP bought a new position in Ultragenyx Pharmaceutical during the fourth quarter worth $27,493,000. Point72 Asset Management L.P. boosted its position in Ultragenyx Pharmaceutical by 81.0% during the fourth quarter. Point72 Asset Management L.P. now owns 1,182,877 shares of the biopharmaceutical company's stock worth $49,764,000 after purchasing an additional 529,217 shares during the period. Finally, Nuveen LLC bought a new position in Ultragenyx Pharmaceutical during the first quarter worth $18,776,000. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Stock Down 1.1%

Shares of RARE stock traded down $0.34 during mid-day trading on Monday, reaching $29.96. 1,340,019 shares of the stock traded hands, compared to its average volume of 1,472,288. The stock's fifty day simple moving average is $30.83 and its two-hundred day simple moving average is $35.06. Ultragenyx Pharmaceutical Inc. has a 1-year low of $25.81 and a 1-year high of $60.37. The company has a market cap of $2.89 billion, a price-to-earnings ratio of -5.42 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. The firm had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business's revenue for the quarter was up 13.2% on a year-over-year basis. During the same period last year, the firm posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on RARE shares. Guggenheim reaffirmed a "buy" rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Cantor Fitzgerald reduced their price objective on shares of Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. William Blair began coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective on the stock. Canaccord Genuity Group lowered their price objective on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Morgan Stanley lowered their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $81.50.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is currently owned by corporate insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.